Golias T, et al. (2016) Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. Sci Rep 6, 31146 27498883

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S232-p - PDHA1 (human) ▲

Modsite: NRyGMGtsVERAAAs SwissProt Entrez-Gene Orthologous residues PDHA1 (human): S232‑p, PDHA1 iso2 (human): S239‑p, PDHA1 iso4 (human): S270‑p, PDHA1 (mouse): S232‑p, PDHA1 (rat): S232‑p, PDHA1 (pig): S231‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  HNSCC, pancreatic cancer, pancreatic carcinoma Relevant cell lines - cell types - tissues:  MIA PaCa-2 (pancreatic), Su.86.86 (pancreatic) Cellular systems studied:  cell lines Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes hypoxia increase hypoxia PDHK1 (human) increase hypoxia increase HIF1A (human) increase shHIF1A inhibits PDP1 (human) increase Downstream Regulation Effect of modification (process):  cell growth, induced Comments:  PDHK1 knockdown resulted in a significantly suppressed tumour growth, and reduced E1¿ phosphorylation on serine 232 and 293 Associated Diseases Diseases Alterations Comments HNSCC increased worse clinical outcome

S293-p - PDHA1 (human) ▲

Modsite: TYRyHGHsMsDPGVs SwissProt Entrez-Gene Orthologous residues PDHA1 (human): S293‑p, PDHA1 iso2 (human): S300‑p, PDHA1 iso4 (human): S331‑p, PDHA1 (mouse): S293‑p, PDHA1 (rat): S293‑p, PDHA1 (pig): S292‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  HNSCC, pancreatic cancer, pancreatic carcinoma Relevant cell lines - cell types - tissues:  MIA PaCa-2 (pancreatic), Su.86.86 (pancreatic) Cellular systems studied:  cell lines Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes hypoxia increase Downstream Regulation Effect of modification (process):  cell growth, induced Comments:  PDHK1 knockdown resulted in a significantly suppressed tumour growth, and reduced E1¿ phosphorylation on serine 232 and 293

S300-p - PDHA1 (human) ▲

Modsite: sMsDPGVsyRtREEI SwissProt Entrez-Gene Orthologous residues PDHA1 (human): S300‑p, PDHA1 iso2 (human): S307‑p, PDHA1 iso4 (human): S338‑p, PDHA1 (mouse): S300‑p, PDHA1 (rat): S300‑p, PDHA1 (pig): S299‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  HNSCC, pancreatic cancer, pancreatic carcinoma Relevant cell lines - cell types - tissues:  MIA PaCa-2 (pancreatic), Su.86.86 (pancreatic) Cellular systems studied:  cell lines Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes hypoxia increase